- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Eiger BioPharmaceuticals (NASDAQ:EIGR), Quotes and News Summary
Eiger BioPharmaceuticals (NASDAQ: EIGR)
Earnings
see more| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-08-04 | ||||||
| REV | |||||||
| Q1 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.640 | -0.640 | 0.0000 | ||||
| REV | 4.040M | 2.673M | -1.367M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Eiger BioPharmaceuticals Questions & Answers
You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.
Other companies in Eiger BioPharmaceuticals’s space includes: Molecular Partners (NASDAQ:MOLN), Outlook Therapeutics (NASDAQ:OTLK), KalVista Pharmaceuticals (NASDAQ:KALV), Precigen (NASDAQ:PGEN) and Burning Rock Biotech (NASDAQ:BNR).
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by Citigroup on Monday, August 9, 2021. The analyst firm set a price target for 27.00 expecting EIGR to rise to within 12 months (a possible 317.96% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $6.46 last updated Today at June 27, 2022, 6:54 PM UTC.
There are no upcoming dividends for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.